Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The purpose of this document is to evaluate the current evidence and provide guidance on the use of vitamin D for the primary prevention of allergic diseases focusing on asthma and/or wheezing, allergic rhinitis, atopic eczema (dermatitis), and food allergy.

Source: Scope and purpose. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D

Study design awaiting verification · The World Allergy Organization Journal · 2016

Original publication title

World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D

Juan José Yepes-Nuñez; Alessandro Fiocchi; Ruby Pawankar; Carlos A. Cuello-Garcia; Yuan Zhang; Gian Paolo Morgano; Kangmo Ahn; Suleiman Al-Hammadi; Arnav Agarwal; Shreyas Gandhi; Kirsten Beyer; Wesley Burks; Giorgio W. Canonica; Motohiro Ebisawa; Rose Kamenwa; Bee Wah Lee; Haiqi Li; Susan Prescott; John J. Riva; Lanny Rosenwasser; Hugh Sampson; Michael Spigler; Luigi Terracciano; Andrea Vereda; Susan Waserman; Holger J. Schünemann; Jan L. Brożek

© Yepes-Nuñez et al. 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

WAO recommendations about vitamin D supplementation for the prevention of allergic diseases support parents, clinicians and other health care professionals in their decisions whether or not to use vitamin D in preventing allergic diseases in healthy, term infants.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

The World Allergy Organization (WAO) convened a guideline panel to develop evidence-based recommendations addressing the use of vitamin D in primary prevention of allergic diseases.

Source: Objective

Abstract: What methods does the paper describe?

Our WAO guideline panel identified the most relevant clinical questions and performed a systematic review of randomized controlled trials and non-randomized studies (NRS), specifically cohort and case-control studies, of vitamin D supplementation for the prevention of allergic diseases. We also reviewed the evidence about values and preferences, and resource requirements (up to January 2015, with an update on January 30, 2016). We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to develop recommendations.

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (doi:10.1186/s40413-016-0108-1) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

Having reviewed the currently available evidence, the WAO guideline panel found no support for the hypothesis that vitamin D supplementation reduces the risk of developing allergic diseases in children. The WAO guideline panel suggest not using vitamin D in pregnant women, breastfeeding mothers, or healthy term infants as a means of preventing the development of allergic diseases. This recommendation does not apply to those mothers and infants who have other indications for prophylactic or therapeutic use of vitamin D. The panel’s recommendations are conditional and supported by very low certainty evidence.

Source: Results

Abstract: Conclusions

WAO recommendations about vitamin D supplementation for the prevention of allergic diseases support parents, clinicians and other health care professionals in their decisions whether or not to use vitamin D in preventing allergic diseases in healthy, term infants.

Source: Conclusions
Authors’ abstract

Background

The prevalence of allergic diseases is approximately 10 % in infants whose parents and siblings do not have allergic diseases and 20Not reported30 % in those with an allergic first-degree relative. Vitamin D is involved in the regulation of the immune system and it may play a role in the development, severity and course of asthma and other allergic diseases.

Objective

The World Allergy Organization (WAO) convened a guideline panel to develop evidence-based recommendations addressing the use of vitamin D in primary prevention of allergic diseases.

Methods

Our WAO guideline panel identified the most relevant clinical questions and performed a systematic review of randomized controlled trials and non-randomized studies (NRS), specifically cohort and case-control studies, of vitamin D supplementation for the prevention of allergic diseases. We also reviewed the evidence about values and preferences, and resource requirements (up to January 2015, with an update on January 30, 2016). We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to develop recommendations.

Results

Having reviewed the currently available evidence, the WAO guideline panel found no support for the hypothesis that vitamin D supplementation reduces the risk of developing allergic diseases in children. The WAO guideline panel suggest not using vitamin D in pregnant women, breastfeeding mothers, or healthy term infants as a means of preventing the development of allergic diseases. This recommendation does not apply to those mothers and infants who have other indications for prophylactic or therapeutic use of vitamin D. The panel’s recommendations are conditional and supported by very low certainty evidence.

Conclusions

WAO recommendations about vitamin D supplementation for the prevention of allergic diseases support parents, clinicians and other health care professionals in their decisions whether or not to use vitamin D in preventing allergic diseases in healthy, term infants.

Electronic supplementary material

The online version of this article (doi:10.1186/s40413-016-0108-1) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D

Juan José Yepes-Nuñez; Alessandro Fiocchi; Ruby Pawankar; Carlos A. Cuello-Garcia; Yuan Zhang; Gian Paolo Morgano; Kangmo Ahn; Suleiman Al-Hammadi; Arnav Agarwal; Shreyas Gandhi; Kirsten Beyer; Wesley Burks; Giorgio W. Canonica; Motohiro Ebisawa; Rose Kamenwa; Bee Wah Lee; Haiqi Li; Susan Prescott; John J. Riva; Lanny Rosenwasser; Hugh Sampson; Michael Spigler; Luigi Terracciano; Andrea Vereda; Susan Waserman; Holger J. Schünemann; Jan L. Brożek

The World Allergy Organization Journal · 2016

© Yepes-Nuñez et al. 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:25:16.207217+00:00

DOI: 10.1186/s40413-016-0108-1 · PMC4869275